• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evernorth Announces New Era of Pharmacy Benefit Services to Lower Americans' Medication Costs

    10/27/25 6:15:00 AM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email

    Unveils Transparent Rebate-Free Pharmacy Benefit; Lower Costs and Better Experience for Americans; Greater Support for Local Pharmacies

    BLOOMFIELD, Conn., Oct. 27, 2025 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI) today announced a new rebate-free pharmacy benefit model designed to help Americans stay healthy and get the medications they need by lowering costs, improving transparency, and supporting local pharmacies so care is always within reach.

    Evernorth Health Services (PRNewsfoto/Evernorth Health Services)

    "While pharmacy benefit managers have already helped the U.S. achieve the lowest prices for generics in the world – which account for 90% of all prescriptions – the cost of brand-name medicines remain out of reach for too many Americans. We applaud President Trump and his Administration for taking decisive action to help lower costs for brand-name medicines that have long been controlled by drug companies," said David M. Cordani, Chairman and CEO, The Cigna Group. "We are building on our long track record of pharmacy benefits innovation to put Americans first – lowering their drug costs, protecting access to their trusted pharmacies, and providing the clinical support and safety checks they need to stay healthy."

    Evernorth's new Express Scripts pharmacy benefit services model is rooted in three core components:

    Transparent, rebate-free pharmacy benefit services

    Evernorth will transition toward a new model where discounts negotiated with drug companies are available upfront to Americans buying their medications. This new approach will cut out the complex post-purchase rebate process by making the discounted price of the drug readily available and transparent from the start.

    For Americans, this means lower costs – particularly for brand-name drugs – at the pharmacy counter, as they will directly benefit from the discounts Evernorth secures. For businesses and other health plans, this means a simpler, more direct path for procuring medications for their benefit plans. It also gives them more real-time visibility into their drug costs, improving their ability to support their population and forecast their budgets.  

    "Pharmacy benefit managers have successfully driven down costs for Americans with generics and now with biosimilars. President Trump has highlighted the urgent need to tackle the high list prices of the 10% of medications that make up 88% of costs," said Adam Kautzner, PharmD, President of Evernorth Care Management and Express Scripts. "In this new era of pharmacy benefits, we're creating more choice for Americans by lowering the costs of expensive brand-name drugs while driving accelerated adoption of generics and biosimilars. Our innovative model is a win-win for Americans and their employers—lower costs for Americans, real-time transparency for employers, and renewed trust in pharmacy benefits for all."

    Cigna Healthcare will adopt this model for its fully insured lives beginning in 2027. It will become the standard model available for all Evernorth pharmacy benefits clients beginning in 2028. 

    Lower costs and better experiences for Americans

    For Americans in health plans where they pay the full cost of medications, including millions of people with high-deductible plans, this new model will reduce their monthly cost for a brand-name prescription by an average of 30%.

    Evernorth is also ensuring Americans pay the lowest available cost for both brand-name and generic medicines – whether it is the Evernorth negotiated price, their copay, or a cash discount price. To do that, Evernorth leverages technology to automatically compare multiple pricing options and charge the lowest cost at the pharmacy counter. For example, if a medicine has:

    • An Evernorth negotiated cost of $22 (70% off the list price),
    • A cash discount cost of $20,
    • A drug company's "direct-to-consumer" cost of $50, or
    • A copay of $25;

    the customer will pay $20, the lowest of the four options. In most cases, the Evernorth-negotiated cost is the best, but there are instances where the cash discount cost is lower, particularly for Americans in high-deductible health plans. Tens of millions of Americans benefit from this technology today and millions more will start benefitting in January 2026. Evernorth plans to integrate this model with new direct-to-patient programs when they become available to ensure the lowest costs are always widely available to Americans.

    By helping Americans use their pharmacy benefit to get the lowest price on medications, Evernorth ensures that their out-of-pocket costs count toward their annual deductible. Americans also receive the protection of Evernorth's robust clinical safeguards, which include thousands of safety checks that help prevent harmful drug interactions, flags allergies, and ensures medications are taken correctly. More than 50% of patients prescribed chronic care medications do not follow their treatment plans consistently, which makes Evernorth's clinical support essential to appropriate medication use and helping Americans achieve better health.

    Customers will also have the option to pay Evernorth's negotiated cost rather than the drug company's list price if a prescribed brand-name medicine is not covered by their health plan – giving customers more choices for how they get their medicines.

    Support for community pharmacies so medications and care are always within reach

    For many Americans, their local pharmacy is the front door to health care and an essential part of their care team. To ensure local pharmacies can continue to play this critical role, Evernorth is adopting a new reimbursement model that compensates pharmacies based on their cost for medications plus a dispensing fee and additional reimbursement for the essential clinical services they provide to patients.

    This forward-thinking approach to clinical reimbursement will recognize and reward pharmacies for the broad range of care services they provide, extending beyond dispensing medications. By setting higher quality standards, pharmacies will have the opportunity to earn additional reimbursement for delivering exceptional patient care and achieving improved health outcomes.

    The new reimbursement model will be implemented across all in-network pharmacies starting in 2026, ensuring that every local pharmacy has the resources and incentives to excel in patient care and service.

    This new pharmacy benefit model builds on the company's decades-long legacy of driving affordability for millions of Americans. From pioneering the use of generics to expanding access to biosimilars, it has consistently led the way in lowering prescription drug costs while ensuring customers have the support and guidance they need to use their medicines correctly. Evernorth is proud to continue its tradition of innovation with this breakthrough new model that improves affordability, access, and health for millions of Americans.

    About Evernorth Health Services 

    Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE:CI), or third-party partners. Learn more at evernorth.com.

    Media Contact: 

    Justine Sessions

    [email protected]

    860-810-6523

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-announces-new-era-of-pharmacy-benefit-services-to-lower-americans-medication-costs-302594769.html

    SOURCE Evernorth

    Get the next $CI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    10/14/2025$370.00Buy
    Goldman
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on The Cigna Group with a new price target

    Goldman initiated coverage of The Cigna Group with a rating of Buy and set a new price target of $370.00

    10/14/25 8:47:37 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group downgraded by Bernstein with a new price target

    Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

    2/6/25 7:05:01 AM ET
    $CI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on The Cigna Group with a new price target

    Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

    6/26/24 7:28:18 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Leadership Updates

    Live Leadership Updates

    View All

    The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

    BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of MPC and Chairman, President and Chief Executive Officer of MPLX. Prior

    6/2/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group's "Community Vitality Project" Donates $75,000 to Nonprofits through Program Encouraging Fitness and Community Engagement

    As part of the company's initiative, thousands of employees logged 280,000 minutes of exercise over nine days Cigna leaders biked to Hartford, Conn.'s Dunkin' Park to host Boys & Girls Clubs members for a Yard Goats baseball game, with surprise appearances by UConn basketball coach and playersBLOOMFIELD, Conn., Sept. 9, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI) put out a challenge to its workforce this summer, inviting colleagues to join its first-ever Community Vitality Project, a nine-day challenge combining fun, fitness and fundraising. By logging more than 280,000 minutes of fitness activities and awarding their minutes spent moving, The Cigna Group employees helped determine how to

    9/9/24 7:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group announces leadership changes to continue driving growth

    Brian Evanko to continue as Chief Financial Officer, will serve as new President and CEO of Cigna HealthcareAnn Dennison to join The Cigna Group as Deputy Chief Financial OfficerMike Triplett to retire by end of 2024 and Bryan Holgerson promoted to President of U.S. Commercial for Cigna HealthcareEric Palmer to assume expanded role leading enterprise strategy and corporate development, will continue as President and CEO of Evernorth Health ServicesBLOOMFIELD, Conn., Jan. 17, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI), a global health company, today announced leadership changes designed to continue accelerating growth across Evernorth Health Services and Cigna Healthcare.

    1/17/24 9:15:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Financials

    Live finance-specific insights

    View All

    The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

    Total revenues for the third quarter 2025 increased 10% to $69.7 billionShareholders' net income for the third quarter 2025 was $1.9 billion, or $6.98 per shareAdjusted income from operations1 for the third quarter 2025 was $2.1 billion, or $7.83 per shareReaffirms 2025 outlook for adjusted income from operations1,2 of at least $29.60 per share2The Cigna Group announced a new rebate-free pharmacy benefit model designed to lower costs, improve transparency, and support local pharmaciesBLOOMFIELD, Conn., Oct. 30, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported third quarter 2025 results that reflect strategic execution across its diverse portfolio of busines

    10/30/25 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Declares Quarterly Dividend

    BLOOMFIELD, Conn., Oct. 22, 2025 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE:CI) today declared a cash dividend of $1.51 per share of its common stock, payable on December 18, 2025 to shareholders of record as of the close of business on December 4, 2025. About The Cigna Group The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and ser

    10/22/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group's Third Quarter 2025 Earnings Release Details

    BLOOMFIELD, Conn., Oct. 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2025 financial results on Thursday, October 30, 2025, and will host a conference call the same day. Third quarter 2025 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:                Live Call               (888) 566-1889 (Domestic)               (773) 799-3989 (International)               Passcode: 1030

    10/2/25 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cigna Group

    SCHEDULE 13G/A - Cigna Group (0001739940) (Subject)

    11/5/25 11:30:18 AM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by The Cigna Group

    10-Q - Cigna Group (0001739940) (Filer)

    10/30/25 12:20:51 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cigna Group (0001739940) (Filer)

    10/30/25 6:15:59 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

    Total revenues for the third quarter 2025 increased 10% to $69.7 billionShareholders' net income for the third quarter 2025 was $1.9 billion, or $6.98 per shareAdjusted income from operations1 for the third quarter 2025 was $2.1 billion, or $7.83 per shareReaffirms 2025 outlook for adjusted income from operations1,2 of at least $29.60 per share2The Cigna Group announced a new rebate-free pharmacy benefit model designed to lower costs, improve transparency, and support local pharmaciesBLOOMFIELD, Conn., Oct. 30, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported third quarter 2025 results that reflect strategic execution across its diverse portfolio of busines

    10/30/25 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Evernorth Announces New Era of Pharmacy Benefit Services to Lower Americans' Medication Costs

    Unveils Transparent Rebate-Free Pharmacy Benefit; Lower Costs and Better Experience for Americans; Greater Support for Local Pharmacies BLOOMFIELD, Conn., Oct. 27, 2025 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI) today announced a new rebate-free pharmacy benefit model designed to help Americans stay healthy and get the medications they need by lowering costs, improving transparency, and supporting local pharmacies so care is always within reach. "While pharmacy benefit managers have already helped the U.S. achieve the lowest prices for

    10/27/25 6:15:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Declares Quarterly Dividend

    BLOOMFIELD, Conn., Oct. 22, 2025 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE:CI) today declared a cash dividend of $1.51 per share of its common stock, payable on December 18, 2025 to shareholders of record as of the close of business on December 4, 2025. About The Cigna Group The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and ser

    10/22/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    Officer Evanko Brian C exercised 6,269 shares at a strike of $139.22 and sold $1,610,400 worth of shares (5,368 units at $300.00), increasing direct ownership by 2% to 52,083 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    10/7/25 5:22:53 PM ET
    $CI
    Medical Specialities
    Health Care

    New insider Koka Durga Prasad claimed ownership of 4,324 shares (SEC Form 3)

    3 - Cigna Group (0001739940) (Issuer)

    9/17/25 5:37:46 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by The Cigna Group

    SC 13G - Cigna Group (0001739940) (Subject)

    11/12/24 9:55:14 AM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/13/24 5:02:29 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/9/24 8:50:20 AM ET
    $CI
    Medical Specialities
    Health Care